Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).
J Immunother Cancer. 2019;7(1):96 - PMID: 30944020 - PMCID: PMC6446400 - DOI: 10.1186/s40425-019-0578-0
Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Am J Ophthalmol. 2019;200:226-241 - PMID: 30633894 - PMCID: PMC7456462 - DOI: 10.1016/j.ajo.2018.12.020
Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
Cancer Immunol Immunother. 2019;68(8):1273-1286 - PMID: 31243491 - PMCID: PMC6684362 - DOI: 10.1007/s00262-019-02357-1
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Peripheral Circulating CD45RA-FOXP3hi T Regulatory (TReg) II Cells Provide a Window into the Activity of Intratumoral TReg Cells.
Trends Cancer. 2019;6(1):3-6 - PMID: 31952778 - PMCID: PMC7390988 - DOI: 10.1016/j.trecan.2019.11.003
High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers.
Methods Enzymol. 2019;635:1-20 - PMID: 32122539 - PMCID: PMC7390987 - DOI: 10.1016/bs.mie.2019.05.039
6
CSV